APTX Stock Price, Aptinyx Inc Quote, Chart

Market Summary

USD0.10

Market Closed

APTX Stock Price

View Fullscreen

APTX RSI Chart

APTX Valuation

Market Cap

6.8M

Price/Earnings (Trailing)

-0.1

Price/Sales (Trailing)

6.77

Price/Free Cashflow

-0.12

APTX Price/Sales (Trailing)

APTX Profitability

Free Cashflow Yield

-817.23%

APTX Fundamentals

APTX Revenue

APTX Earnings

Breaking Down APTX Revenue

Last 7 days

11.1%

Last 30 days

66.7%

Trailing 12 Months

-70.4%

How does APTX drawdown profile look like?

APTX Financial Health

APTX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	1.7M	1.3M	1.0M	1.0M
2020	3.6M	3.2M	2.5M	1.6M
2019	5.0M	3.8M	3.8M	3.7M
2018	5.4M	5.8M	6.2M	6.6M
2017	0	0	0	5.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aptinyx Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 13, 2022	miller joan w.	bought	50,091	2.83	17,700	-
Dec 06, 2021	riedel norbert g	bought	223,000	2.23	100,000	ceo
Dec 02, 2021	khanna ashish	bought	101,700	2.26	45,000	cfo and cbo
Nov 12, 2021	hombach robert j.	bought	179,040	2.4	74,600	-
Nov 11, 2021	hombach robert j.	bought	12,960	2.4	5,400	-
May 17, 2021	riedel norbert g	acquired	-	-	380,000	ceo
May 17, 2021	riedel norbert g	sold (taxes)	-322,003	2.53	-127,274	ceo
May 17, 2021	khanna ashish	sold (taxes)	-96,367	2.53	-38,090	cfo and cbo

Are Funds Buying or Selling APTX?

Are funds buying APTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own APTX

No. of Funds

Unveiling Aptinyx Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	artal international s.c.a.	0%	0	SC 13G/A
Jun 27, 2023	adams street partners llc	8.0%	5,395,996	SC 13D/A
Mar 16, 2023	longitude capital partners ii, llc	0%	0	SC 13D/A
Feb 14, 2023	longitude capital partners ii, llc	5.0%	3,356,746	SC 13D/A
Feb 13, 2023	artal international s.c.a.	9.0%	6,116,493	SC 13G/A
Jan 20, 2023	kryzanowski john a	9.8%	6,637,800	SC 13G/A
Jun 24, 2022	kryzanowski john a	5.77%	1,942,680	SC 13G/A
Jun 24, 2022	kryzanowski john a	7.42%	4,695,800	SC 13G/A
Jun 24, 2022	kryzanowski john a	8.70%	5,890,802	SC 13G/A
Jun 24, 2022	kryzanowski john a	5.10%	1,781,291	SC 13G

Recent SEC filings of Aptinyx Inc

View All Filings

Date Filed	Form Type	Document
Feb 09, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Aptinyx Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Aptinyx Inc News

Latest updates

Aptinyx Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2
Revenue	-	-	-	-	1,000	-	257	490	818	918	936	925	890	1,039	943	2,128	2,464	1,835	1,205	1,428
Operating Expenses	-9.6%	19,172	21,206	19,866	15,290	11,561	11,680	13,135	15,954	15,131	16,284	13,652	18,215	15,749	15,732	15,708	14,273	-	9,385	9,469
S&GA Expenses	3.8%	5,116	4,928	5,070	4,976	4,775	5,050	4,770	4,899	4,533	4,523	4,171	5,725	4,821	3,782	2,022	2,049	-	1,318	1,268
R&D Expenses	-13.7%	14,056	16,278	14,796	10,314	6,786	6,630	8,365	11,055	10,598	11,761	9,481	12,490	10,928	11,950	13,686	12,224	-	8,067	8,201
Interest Expenses	-100.0%	-	72.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	7.6%	-19,610	-21,231	-19,819	-14,226	-11,488	-11,338	-12,517	-14,710	-13,778	-14,790	-12,131	-16,711	-14,093	-14,181	-13,335	-11,672	-	-8,145	-7,999
Net Income Margin	-12.2%	-74.89*	-66.76*	-45.24*	-28.37*	-31.98*	-21.08*	-17.65*	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-2.4%	-19,060	-18,610	-16,771	-8,984	-7,913	-13,277	-9,816	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2017Q4
Assets	-28.1%	48.00	67.00	76.00	92.00	107	115	133	134	153	151	114	121	127	106	120	130	141	156	170	183	97.00
Current Assets	-25.4%	48.00	64.00	74.00	92.00	107	115	132	134	152	150	113	120	126	105	119	128	139	153	168	180	95.00
Cash Equivalents	-20.7%	45.00	56.00	67.00	85.00	100	106	125	129	147	141	104	116	121	99.00	115	125	137	151	166	180	93.00
Net PPE	-100.0%	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00
Liabilities	4.6%	30.00	28.00	27.00	30.00	29.00	20.00	21.00	3.00	4.00	5.00	4.00	4.00	5.00	5.00	7.00	5.00	6.00	6.00	8.00	8.00	5.00
Current Liabilities	48.2%	9.00	6.00	3.00	6.00	5.00	6.00	6.00	3.00	4.00	5.00	4.00	4.00	5.00	5.00	7.00	5.00	6.00	6.00	8.00	7.00	4.00
Long Term Debt	-12.0%	19.00	22.00	25.00	24.00	24.00	14.00	14.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	102.3%	6.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-12.0%	19.00	22.00	25.00	24.00	24.00	14.00	14.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-52.3%	18.00	38.00	49.00	62.00	77.00	95.00	112	131	149	146	110	117	123	101	113	125	135	149	162	176	-
Retained Earnings	-6.0%	-373	-352	-340	-325	-307	-287	-268	-247	-227	-213	-201	-190	-177	-162	-149	-134	-122	-105	-91.44	-77.26	-52.26
Additional Paid-In Capital	0.3%	391	390	389	387	385	382	380	377	375	358	311	307	300	264	262	259	257	255	253	252	12.00
Shares Outstanding	0%	68.00	68.00	68.00	68.00	68.00	68.00	67.00	67.00	66.00	63.00	47.00	46.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	38*	-	-	-	136	-	-	-	195	-	-	-	62.00	-	-	-	368	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Cashflow From Operations	-9.5%	-11,365	-10,377	-18,625	-14,758	-15,924	-19,060	-18,610	-16,771	-8,984	-7,913	-13,098	-9,792	-11,553	-15,460	-10,697	-11,787	-14,143	-14,983	-12,255	-10,774	-9,436
Share Based Compensation	-32.9%	1,037	1,545	1,996	2,281	2,350	2,324	2,262	2,478	2,655	2,476	2,669	2,503	2,331	2,070	2,641	2,325	2,000	1,334	720	740	524
Cashflow From Investing	-	-	-	-	-	-	-1.00	1.00	31.00	90.00	-	-179	-24.00	-11.00	4.00	-	-	-	-16.00	-69.00	-276	-46.00
Cashflow From Financing	-13250.0%	-267	-2.00	-78.00	-133	9,960	-105	14,599	-844	14,676	45,131	1,135	4,674	33,735	91.00	-126	141	86.00	58.00	-1,170	107,790	-304

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

APTX Income Statement

2023-03-31

Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 16,093	$ 13,602
General and administrative	4,229	5,777
Total operating expenses	20,322	19,379
Loss from operations	(20,322)	(19,379)
Other (income) expense, net	(286)	(29)
Interest expense	1,030	477
Net loss and comprehensive loss	$ (21,066)	$ (19,827)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.31)	$ (0.29)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.31)	$ (0.29)
Weighted-average number of common shares outstanding, basic (in shares)	67,716	67,716
Weighted-average number of common shares outstanding, diluted (in shares)	67,716	67,716

APTX Balance Sheet

2023-03-31

Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 44,573	$ 56,205
Short-term restricted cash	179	179
Prepaid expenses and other current assets	3,005	7,646
Total current assets	47,757	64,030
Other assets	206	2,622
Property and equipment, net		32
Total assets	47,963	66,684
Current liabilities:
Accounts payable	1,374	724
Accrued expenses and other current liabilities	1,157	2,772
Finance lease, current	1,138
Term loan, current	5,654	2,795
Total current liabilities	9,323	6,291
Finance lease, non-current	940
Term loan, non-current	19,444	22,108
Total liabilities	29,707	28,399
Commitments and contingencies (see Note 12)
Stockholders' equity:
Preferred stock, $0.01 par value, 10,000 shares authorized and no shares issued and outstanding as of March 31, 2023 and December 31, 2022
Common stock, $0.01 par value, 150,000 shares authorized as of March 31, 2023 and December 31, 2022, 67,716 issued and outstanding as of March 31, 2023 and December 31, 2022	677	677
Additional paid-in capital	391,381	390,344
Accumulated deficit	(373,802)	(352,736)
Total stockholders' equity	18,256	38,285
Total liabilities and stockholders' equity	$ 47,963	$ 66,684

About Aptinyx Inc

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

WEBSITE	aptinyx.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Aptinyx Inc Frequently Asked Questions

What is the ticker symbol for Aptinyx Inc? What does APTX stand for in stocks?

APTX is the stock ticker symbol of Aptinyx Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aptinyx Inc (APTX)?

As of Fri Dec 29 2023, market cap of Aptinyx Inc is 6.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APTX stock?

You can check APTX's fair value in chart for subscribers.

What is the fair value of APTX stock?

You can check APTX's fair value in chart for subscribers. The fair value of Aptinyx Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aptinyx Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aptinyx Inc a good stock to buy?

The fair value guage provides a quick view whether APTX is over valued or under valued. Whether Aptinyx Inc is cheap or expensive depends on the assumptions which impact Aptinyx Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APTX.

What is Aptinyx Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 29 2023, APTX's PE ratio (Price to Earnings) is -0.1 and Price to Sales (PS) ratio is 6.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APTX PE ratio will change depending on the future growth rate expectations of investors.